Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4494 entries
Sorted by: Best Match Show Resources per page
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population

veteran

[No authors listed]
GSID: zw-kGqYqGxgJ
T Patil, M Lebrecht - Thrombosis Research, 2020 - Elsevier

… The goal of this study is to evaluate the use of DOACs in morbidly obese veteran population … A retrospective single center cohort study was conducted in morbidly obese veteran patients …

Cite
Patil, T., & Lebrecht, M. (2020). A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thrombosis Research, 192, 124-130.
Patil, Tanvi, and Morgan Lebrecht. "A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population." Thrombosis Research 192 (2020): 124-130.
Copy Download .nbib Format: MLA
Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed.

Patient preference and adherence

Crivera C, Nelson WW, Schein JR, Witt EA.
PMID: 27274206
Patient Prefer Adherence. 2016 May 17;10:795-805. doi: 10.2147/PPA.S106215. eCollection 2016.

BACKGROUND: Atrial fibrillation (AF) is associated with an increased risk of stroke. Anticoagulant (AC) therapies are effective at treating AF, but carry with them an increased risk of bleed. Research suggests that a large proportion of AF patients who...

Cite
Crivera C, Nelson WW, Schein JR, et al. Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. Patient Prefer Adherence. 2016;10:795-805doi: 10.2147/PPA.S106215.
Crivera, C., Nelson, W. W., Schein, J. R., & Witt, E. A. (2016). Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. Patient preference and adherence, 10795-805. https://doi.org/10.2147/PPA.S106215
Crivera, Concetta, et al. "Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed." Patient preference and adherence vol. 10 (2016): 795-805. doi: https://doi.org/10.2147/PPA.S106215
Crivera C, Nelson WW, Schein JR, Witt EA. Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. Patient Prefer Adherence. 2016 May 17;10:795-805. doi: 10.2147/PPA.S106215. eCollection 2016. PMID: 27274206; PMCID: PMC4876102.
Copy Download .nbib Format: NLM
A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits.

Thrombosis journal

Amin A, Deitelzweig S.
PMID: 26300695
Thromb J. 2015 Aug 21;13:29. doi: 10.1186/s12959-015-0056-y. eCollection 2015.

Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin has limitations that have motivated development of several novel...

Cite
Amin A, Deitelzweig S. A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thromb J. 2015;13:29doi: 10.1186/s12959-015-0056-y.
Amin, A., & Deitelzweig, S. (2015). A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thrombosis journal, 1329. https://doi.org/10.1186/s12959-015-0056-y
Amin, Alpesh, and Deitelzweig, Steven. "A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits." Thrombosis journal vol. 13 (2015): 29. doi: https://doi.org/10.1186/s12959-015-0056-y
Amin A, Deitelzweig S. A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thromb J. 2015 Aug 21;13:29. doi: 10.1186/s12959-015-0056-y. eCollection 2015. PMID: 26300695; PMCID: PMC4546218.
Copy Download .nbib Format: NLM
Thromboembolism and anticoagulation after Fontan surgery.

Annals of pediatric cardiology

Viswanathan S.
PMID: 27625521
Ann Pediatr Cardiol. 2016 Sep-Dec;9(3):236-40. doi: 10.4103/0974-2069.189109.

This review attempts to answer the common questions faced by a clinician regarding thromboembolism and thromboprophylaxis in patients following Fontan surgery. The review is in an easy to understand question and answer format and discusses the currently available literature...

Cite
Viswanathan S. Thromboembolism and anticoagulation after Fontan surgery. Ann Pediatr Cardiol. 2016;9(3):236-40doi: 10.4103/0974-2069.189109.
Viswanathan, S. (2016). Thromboembolism and anticoagulation after Fontan surgery. Annals of pediatric cardiology, 9(3), 236-40. https://doi.org/10.4103/0974-2069.189109
Viswanathan, Sangeetha. "Thromboembolism and anticoagulation after Fontan surgery." Annals of pediatric cardiology vol. 9,3 (2016): 236-40. doi: https://doi.org/10.4103/0974-2069.189109
Viswanathan S. Thromboembolism and anticoagulation after Fontan surgery. Ann Pediatr Cardiol. 2016 Sep-Dec;9(3):236-40. doi: 10.4103/0974-2069.189109. PMID: 27625521; PMCID: PMC5007932.
Copy Download .nbib Format: NLM
Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach.

Cureus

Chintalacheruvu LM, Bhatty O, Andukuri VG.
PMID: 28924530
Cureus. 2017 Jul 07;9(7):e1444. doi: 10.7759/cureus.1444.

In the last few decades many new anticoagulants (i.e direct thrombin and factor ten inhibitors) have been introduced with efficacy that rivals older drugs in the treatment of venous thromboembolism (VTE). However, for all their success, management of patients...

Cite
Chintalacheruvu LM, Bhatty O, Andukuri VG. Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. Cureus. 2017;9(7):e1444doi: 10.7759/cureus.1444.
Chintalacheruvu, L. M., Bhatty, O., & Andukuri, V. G. (2017). Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. Cureus, 9(7), e1444. https://doi.org/10.7759/cureus.1444
Chintalacheruvu, Lakshmi Manogna, et al. "Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach." Cureus vol. 9,7 (2017): e1444. doi: https://doi.org/10.7759/cureus.1444
Chintalacheruvu LM, Bhatty O, Andukuri VG. Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. Cureus. 2017 Jul 07;9(7):e1444. doi: 10.7759/cureus.1444. PMID: 28924530; PMCID: PMC5589500.
Copy Download .nbib Format: NLM
Comparison of Perioperative Blood Loss in Primary Non-cemented Total Hip Arthroplasty for Rapidly Destructive Coxarthrosis and Osteonecrosis of the Femoral Head.

Hip & pelvis

Song JH, Han SK, Lee KH, Lee JM, Lee KH.
PMID: 27536617
Hip Pelvis. 2015 Sep;27(3):141-5. doi: 10.5371/hp.2015.27.3.141. Epub 2015 Sep 30.

PURPOSE: The purpose of this study is to compare the perioperative blood loss in primary non-cemented total hip arthroplasty (THA) performed for rapidly destructive coxarthrosis (RDC) with the perioperative blood loss in primary non-cemented THA for typical osteonecrosis of...

Cite
Song JH, Han SK, Lee KH, et al. Comparison of Perioperative Blood Loss in Primary Non-cemented Total Hip Arthroplasty for Rapidly Destructive Coxarthrosis and Osteonecrosis of the Femoral Head. Hip Pelvis. 2015;27(3):141-5doi: 10.5371/hp.2015.27.3.141.
Song, J. H., Han, S. K., Lee, K. H., Lee, J. M., & Lee, K. H. (2015). Comparison of Perioperative Blood Loss in Primary Non-cemented Total Hip Arthroplasty for Rapidly Destructive Coxarthrosis and Osteonecrosis of the Femoral Head. Hip & pelvis, 27(3), 141-5. https://doi.org/10.5371/hp.2015.27.3.141
Song, Joo-Hyoun, et al. "Comparison of Perioperative Blood Loss in Primary Non-cemented Total Hip Arthroplasty for Rapidly Destructive Coxarthrosis and Osteonecrosis of the Femoral Head." Hip & pelvis vol. 27,3 (2015): 141-5. doi: https://doi.org/10.5371/hp.2015.27.3.141
Song JH, Han SK, Lee KH, Lee JM, Lee KH. Comparison of Perioperative Blood Loss in Primary Non-cemented Total Hip Arthroplasty for Rapidly Destructive Coxarthrosis and Osteonecrosis of the Femoral Head. Hip Pelvis. 2015 Sep;27(3):141-5. doi: 10.5371/hp.2015.27.3.141. Epub 2015 Sep 30. PMID: 27536617; PMCID: PMC4972718.
Copy Download .nbib Format: NLM
Venous Thromboembolism - Current Diagnostic and Treatment Modalities.

Open access Macedonian journal of medical sciences

Bosevski M, Srbinovska-Kostovska E.
PMID: 27703586
Open Access Maced J Med Sci. 2016 Sep 15;4(3):523-525. doi: 10.3889/oamjms.2016.087. Epub 2016 Aug 24.

BACKGROUND: Pulmonary embolism and deep venous thrombosis, known as venous thromboembolism (VTE), are associated with a high proportion of morbidity and mortality.AIM: Aim of this review is to emphasise current diagnostic and therapeutic modalities for VTE.RESULTS: No differences have...

Cite
Bosevski M, Srbinovska-Kostovska E. Venous Thromboembolism - Current Diagnostic and Treatment Modalities. Open Access Maced J Med Sci. 2016;4(3):523-525doi: 10.3889/oamjms.2016.087.
Bosevski, M., & Srbinovska-Kostovska, E. (2016). Venous Thromboembolism - Current Diagnostic and Treatment Modalities. Open access Macedonian journal of medical sciences, 4(3), 523-525. https://doi.org/10.3889/oamjms.2016.087
Bosevski, Marijan, and Srbinovska-Kostovska, Elizabeta. "Venous Thromboembolism - Current Diagnostic and Treatment Modalities." Open access Macedonian journal of medical sciences vol. 4,3 (2016): 523-525. doi: https://doi.org/10.3889/oamjms.2016.087
Bosevski M, Srbinovska-Kostovska E. Venous Thromboembolism - Current Diagnostic and Treatment Modalities. Open Access Maced J Med Sci. 2016 Sep 15;4(3):523-525. doi: 10.3889/oamjms.2016.087. Epub 2016 Aug 24. PMID: 27703586; PMCID: PMC5042646.
Copy Download .nbib Format: NLM
Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study).

Journal of arrhythmia

Kusakawa K, Harada KH, Kagimura T, Koizumi A.
PMID: 28416974
J Arrhythm. 2017 Apr;33(2):99-106. doi: 10.1016/j.joa.2016.06.006. Epub 2016 Aug 11.

BACKGROUND: Oral anticoagulants (OACs) can help prevent stroke in patients with nonvalvular atrial fibrillation (NVAF). The aim of this study was to characterize the use of OACs other than direct thrombin inhibitors (DTIs) for NVAF.METHODS: Patients with NVAF taking...

Cite
Kusakawa K, Harada KH, Kagimura T, et al. Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm. 2016;33(2):99-106doi: 10.1016/j.joa.2016.06.006.
Kusakawa, K., Harada, K. H., Kagimura, T., & Koizumi, A. (2017). Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). Journal of arrhythmia, 33(2), 99-106. https://doi.org/10.1016/j.joa.2016.06.006
Kusakawa, Koichi, et al. "Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study)." Journal of arrhythmia vol. 33,2 (2017): 99-106. doi: https://doi.org/10.1016/j.joa.2016.06.006
Kusakawa K, Harada KH, Kagimura T, Koizumi A. Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm. 2017 Apr;33(2):99-106. doi: 10.1016/j.joa.2016.06.006. Epub 2016 Aug 11. PMID: 28416974; PMCID: PMC5388034.
Copy Download .nbib Format: NLM
Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa).

Journal of arrhythmia

Hatori Y, Sakai H, Kunishima T, Hatori N, Chen L, Ishigami T, Satoh N.
PMID: 28416976
J Arrhythm. 2017 Apr;33(2):111-116. doi: 10.1016/j.joa.2016.07.008. Epub 2016 Aug 23.

BACKGROUND: Atrial fibrillation (AF) is one of the most prevalent cardiac arrhythmias associated with substantially increased risks of ischemic stroke and thromboembolism. Oral anticoagulants (OACs) are the cornerstone of AF management and effectively prevent AF-related stroke. As new non-vitamin...

Cite
Hatori Y, Sakai H, Kunishima T, et al. Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). J Arrhythm. 2016;33(2):111-116doi: 10.1016/j.joa.2016.07.008.
Hatori, Y., Sakai, H., Kunishima, T., Hatori, N., Chen, L., Ishigami, T., Satoh, N. (2017). Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). Journal of arrhythmia, 33(2), 111-116. https://doi.org/10.1016/j.joa.2016.07.008
Hatori, Yutaka, et al. "Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa)." Journal of arrhythmia vol. 33,2 (2017): 111-116. doi: https://doi.org/10.1016/j.joa.2016.07.008
Hatori Y, Sakai H, Kunishima T, Hatori N, Chen L, Ishigami T, Satoh N. Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). J Arrhythm. 2017 Apr;33(2):111-116. doi: 10.1016/j.joa.2016.07.008. Epub 2016 Aug 23. PMID: 28416976; PMCID: PMC5388051.
Copy Download .nbib Format: NLM
Cheminformatics-Based Anticoagulant Study of Traditionally Used Medicinal Plants.

Iranian biomedical journal

Alikhani Pour M, Sardari S, Eslamifar A, Azhar A, Rezvani M, Nazari M.
PMID: 28454485
Iran Biomed J. 2017 Nov;21(6):400-5. doi: 10.18869/acadpub.ibj.21.6.400. Epub 2017 Apr 29.

BACKGROUNG: Medicinal plants, as a complementary medicine, have been used to treat various diseases since ancient times. These plants have numerous beneficial applications and are the source of certain conventional drugs. In diseases such as stroke and ischemia, which...

Cite
Alikhani Pour M, Sardari S, Eslamifar A, et al. Cheminformatics-Based Anticoagulant Study of Traditionally Used Medicinal Plants. Iran Biomed J. 2017;21(6):400-5doi: 10.18869/acadpub.ibj.21.6.400.
Alikhani Pour, M., Sardari, S., Eslamifar, A., Azhar, A., Rezvani, M., & Nazari, M. (2017). Cheminformatics-Based Anticoagulant Study of Traditionally Used Medicinal Plants. Iranian biomedical journal, 21(6), 400-5. https://doi.org/10.18869/acadpub.ibj.21.6.400
Alikhani Pour, Mahdi, et al. "Cheminformatics-Based Anticoagulant Study of Traditionally Used Medicinal Plants." Iranian biomedical journal vol. 21,6 (2017): 400-5. doi: https://doi.org/10.18869/acadpub.ibj.21.6.400
Alikhani Pour M, Sardari S, Eslamifar A, Azhar A, Rezvani M, Nazari M. Cheminformatics-Based Anticoagulant Study of Traditionally Used Medicinal Plants. Iran Biomed J. 2017 Nov;21(6):400-5. doi: 10.18869/acadpub.ibj.21.6.400. Epub 2017 Apr 29. PMID: 28454485; PMCID: PMC5572436.
Copy Download .nbib Format: NLM
Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?.

European heart journal. Cardiovascular pharmacotherapy

Goto S, Goto S.
PMID: 27533975
Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):83-5. doi: 10.1093/ehjcvp/pvu017. Epub 2015 Feb 19.

No abstract available.

Cite
Goto S, Goto S. Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):83-5doi: 10.1093/ehjcvp/pvu017.
Goto, S., & Goto, S. (2015). Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. European heart journal. Cardiovascular pharmacotherapy, 1(2), 83-5. https://doi.org/10.1093/ehjcvp/pvu017
Goto, Shinichi, and Goto, Shinya. "Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?." European heart journal. Cardiovascular pharmacotherapy vol. 1,2 (2015): 83-5. doi: https://doi.org/10.1093/ehjcvp/pvu017
Goto S, Goto S. Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):83-5. doi: 10.1093/ehjcvp/pvu017. Epub 2015 Feb 19. PMID: 27533975.
Copy Download .nbib Format: NLM
Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Journal of blood medicine

Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG.
PMID: 28979172
J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017.

Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent...

Cite
Kaatz S, Bhansali H, Gibbs J, et al. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017;8:141-149doi: 10.2147/JBM.S121550.
Kaatz, S., Bhansali, H., Gibbs, J., Lavender, R., Mahan, C. E., & Paje, D. G. (2017). Reversing factor Xa inhibitors - clinical utility of andexanet alfa. Journal of blood medicine, 8141-149. https://doi.org/10.2147/JBM.S121550
Kaatz, Scott, et al. "Reversing factor Xa inhibitors - clinical utility of andexanet alfa." Journal of blood medicine vol. 8 (2017): 141-149. doi: https://doi.org/10.2147/JBM.S121550
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017. PMID: 28979172; PMCID: PMC5602457.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4494 entries